Hua Medicine has announced the first innovative diabetes drug, Dozaglietin. (Dorzagliatin’s NDA application was accepted by the National Medical Products Administration’s (NMPA) Center for New Drug Evaluation (CDE).
Dozaglietin was the first glucokinase activator (GKA) drug used to treat diabetes, filing a new drug marketing application worldwide. It is expected to be the world’s first innovative drug (FIC) to be first marketed in China.
Dozaglietin is the world’s first new GKA diabetes drug submitted for the NDA, with innovative mechanisms, new goals, new structures, new compounds, and new therapeutic effects. Dozaglietin is the world’s first new oral treatment for diabetes introduced by a Chinese biotechnology company. Its new mechanism of action directly attacks the underlying cause of type 2 diabetes.
By repairing the damaged glucokinase sensor function in diabetics, Dozaglietin Tatin can significantly improve β-cell function and reduce insulin resistance in patients with type 2 diabetes, effectively control the progression of type 2 diabetes, and broad therapeutic prospects in patients with diabetes have nephropathy.
As part of promoting the commercialization of Dozaglietin, Hua Medicine signed a strategic cooperation agreement with the global pharmaceutical giant and a leader in diabetes treatment in China in August 2020. The two parties will join forces. Hua Medicine’s ability to innovate and Bayer’s leading edge in diabetes management in China have enabled this world’s first innovative drug to help Chinese diabetics as quickly as possible. In September the company was awarded the Dozaglietin by the Shanghai Drug Administration. The “Pharmaceutical Production License” completes the core work of preparation for commercial production.
